MIAMI, Sept. 20, 2007 (PRIME NEWSWIRE) -- Galea Life Sciences, Inc. (Pink Sheets:GLSN) has announced that it has appointed Paul Zuromski as President. Galea Life Sciences focuses on the development of advanced life science technologies. The Company recently acquired BioSource Therapeutics, Inc., a company that develops specialized advanced nutritional supplement products used by patients undergoing specific medically prescribed treatments.
BioSource Therapeutics has developed Nutraplete(tm) Immune System Formula Therapeutic Drink Mix, the first dietary therapeutic supplement designed specifically for people living with HIV/AIDS. Studies have shown that proper nutritional supplementation is critical in assisting the patient with their adherence and tolerance of antiviral drug therapy. Nutraplete can help manage symptoms, promote response to medical treatment, and increase the quality of life by improving daily functioning. Nutraplete is the first in a planned series of innovative dietary therapeutic product formulations targeted towards conditions including chemotherapy, gastric bypass and geriatric applications.
The Joint United Nations Programme on HIV/AIDS estimated that in 2006 there were up to 2.2 million people in North America living with HIV/AIDS and up to 47.1 million worldwide.
Mr. Zuromski brings over 30 years of marketing, management and operations experience to his new post at Galea Life Sciences. He was formerly President of Island Publishing Company, an international publishing and marketing firm directly involved in the nutritional product field. He has also provided professional and consulting services to public and private entities. In his new role with Galea Life Sciences, Mr. Zuromski will be assisting in the continued development of BioSource Therapeutics in the marketplace and spearheading Galea Life Sciences' mission of acquiring and incubating promising new technologies in the emerging field of advanced life sciences. Mr. Zuromski has also been appointed to the Company's Board of Directors.
About Galea Life Sciences, Inc.
Galea Life Sciences, Inc. (Pink Sheets:GLSN) is a non-reporting over-the-counter publicly traded company. Galea Life Sciences identifies and acquires new and innovative life science technologies with outstanding growth potential.
BioSource Therapeutics, Inc., a GLSN subsidiary, is an entrepreneurial life sciences company specializing in the formulation and marketing of specialized advanced nutritional supplement products that benefit people undergoing medically prescribed treatments and therapies.
For more information: www.nutraplete.com
Certain statements in this release constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast," "project," "intend," "expect" "should," "would," and similar expressions and all statements, which are not historical facts, are intended to identify forward-looking statements. These forward-looking statements involve and are subject to known and unknown risks, uncertainties and other factors which could cause the Company's actual results, performance (finance or operating) or achievements to differ from future results, performance (financing and operating) or achievements expressed or implied by such forward-looking statements.
Statements herein express management's beliefs and expectations regarding future performance and are forward-looking and involve risks and uncertainties, including, but not limited to, the ability to negotiate outstanding prior debts of acquired companies; properly identify acquisition partners; adequately perform due diligence; manage and integrate acquired businesses; react to quarterly fluctuations in results; raise working capital and secure other financing; respond to competition and rapidly changing technology; deal with market and stock price fluctuations; and other risks.